Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs?

Bente Glintborg*, Rikke Ibsen, Rebecca Elisabeth Qwist Bilbo, Merete Lund Hetland, Jakob Kjellberg

*Corresponding author af dette arbejde
8 Citationer (Scopus)
1 Downloads (Pure)

Fingeraftryk

Dyk ned i forskningsemnerne om 'Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs?'. Sammen danner de et unikt fingeraftryk.

Keyphrases

Nursing and Health Professions

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science